Health Catalyst (NASDAQ:HCAT) Given New $10.00 Price Target at Wells Fargo & Company

Health Catalyst (NASDAQ:HCAT) had its price target dropped by stock analysts at Wells Fargo & Company from $13.00 to $10.00 in a research report issued on Tuesday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Wells Fargo & Company‘s price target suggests a potential upside of 78.25% from the stock’s previous close.

Other analysts have also issued reports about the company. Canaccord Genuity Group lowered their price target on Health Catalyst from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday. KeyCorp upgraded Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price target for the company in a research report on Wednesday, January 8th. Stephens boosted their price target on Health Catalyst from $7.00 to $9.00 and gave the stock an “equal weight” rating in a research report on Thursday, November 14th. Royal Bank of Canada dropped their price target on Health Catalyst from $9.00 to $7.00 and set a “sector perform” rating for the company in a research report on Wednesday, January 15th. Finally, Citigroup dropped their price target on Health Catalyst from $10.50 to $10.00 and set a “buy” rating for the company in a research report on Friday, January 10th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Health Catalyst presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.91.

Health Catalyst Stock Down 1.2 %

Shares of HCAT opened at $5.61 on Tuesday. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. Health Catalyst has a 12 month low of $5.35 and a 12 month high of $10.99. The stock’s 50 day moving average is $7.45 and its two-hundred day moving average is $7.52. The firm has a market cap of $341.37 million, a P/E ratio of -4.16 and a beta of 1.36.

Health Catalyst (NASDAQ:HCAT) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The business had revenue of $76.40 million during the quarter, compared to analyst estimates of $76.27 million. During the same period in the previous year, the business posted ($0.22) earnings per share. The firm’s revenue for the quarter was up 3.5% on a year-over-year basis. Analysts predict that Health Catalyst will post -0.33 earnings per share for the current fiscal year.

Insider Buying and Selling at Health Catalyst

In other news, insider Kevin Lee Freeman sold 7,500 shares of the company’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $8.94, for a total value of $67,050.00. Following the transaction, the insider now owns 236,950 shares of the company’s stock, valued at $2,118,333. This represents a 3.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Daniel Lesueur sold 5,209 shares of the company’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $7.70, for a total value of $40,109.30. Following the completion of the transaction, the chief operating officer now directly owns 129,690 shares in the company, valued at approximately $998,613. This trade represents a 3.86 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 81,169 shares of company stock worth $639,174 in the last three months. 2.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Health Catalyst

Several hedge funds have recently bought and sold shares of the company. First Light Asset Management LLC raised its position in Health Catalyst by 438.5% in the 2nd quarter. First Light Asset Management LLC now owns 3,956,089 shares of the company’s stock valued at $25,279,000 after purchasing an additional 3,221,408 shares in the last quarter. Millennium Management LLC raised its position in Health Catalyst by 96.3% in the 2nd quarter. Millennium Management LLC now owns 2,413,280 shares of the company’s stock valued at $15,421,000 after purchasing an additional 1,184,131 shares in the last quarter. Nepsis Inc. raised its position in Health Catalyst by 67.9% in the 3rd quarter. Nepsis Inc. now owns 2,104,528 shares of the company’s stock valued at $17,131,000 after purchasing an additional 851,448 shares in the last quarter. Fred Alger Management LLC acquired a new stake in Health Catalyst in the 3rd quarter valued at about $6,858,000. Finally, Portolan Capital Management LLC acquired a new stake in Health Catalyst in the 3rd quarter valued at about $5,402,000. Institutional investors and hedge funds own 85.00% of the company’s stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.